Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$8.93M+22.13%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David L. Fischel
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 131
- Beta
- 1.40
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -9.68
Financials
Revenue
$8.93M+22.1%Net Income
$-6.48M-217.1%EBITDA
$-6.44MFree Cash Flow
$-4.20MEPS (diluted)
$-0.07-128.0%Shares Outstanding (diluted)
102.55M+370.2%Operating Expenses
$10.43MCash & Debt
$3.98MReturn of Capital
$0.00Revenue by Segment (annual)
$32.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.38M | $-21.64M | $-0.25 |
| 2024 | $26.92M | $-24.05M | $-0.30 |
| 2023 | $26.77M | $-20.71M | $-0.27 |
| 2022 | $28.15M | $-18.29M | $-0.26 |
| 2021 | $35.02M | $-10.72M | $-0.16 |
| 2020 | $26.63M | $-6.65M | $-0.11 |
| 2019 | $28.90M | $-4.59M | $-0.07 |
| 2018 | $29.35M | $116.8K | $0.00 |
| 2017 | $31.14M | $-5.89M | $-0.26 |
| 2016 | $32.16M | $-5.29M | $-0.24 |
| 2015 | $37.67M | $-7.35M | $-0.35 |
| 2014 | $35.01M | $-5.20M | $-0.26 |
| 2013 | $38.03M | $-68.76M | $-5.95 |
| 2012 | $46.56M | $-9.24M | $-1.25 |
Valuation
STXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·20d ago·Positive
…ntion Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT ST. LOUIS and ROUEN, France, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the findings from the first-in-human clinical results for Robocath's next-generation robotic system during the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. The findings support a favor…
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Nav…
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026 ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 third quarter on Tuesday, November 10, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss…
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Positive
Stereotaxis Q2 Earnings Call Highlights Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
View source ↗ - Newszacks.com·103d ago·Negative
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
View source ↗ - Newsglobenewswire.com·103d ago·Neutral
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $-0.05 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.07 vs $-0.05miss
- Tue, Aug 11$-0.05 vs $-0.05beat
- Tue, May 12$-0.03 vs $-0.04beat
- Mon, Mar 9$-0.06 vs $-0.06beat
- Tue, Nov 11$-0.03 vs $-0.06beat
- Thu, Aug 7$-0.05 vs $-0.07beat
Estimates and results for STXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STXS officers and directors.
- Bought
- $671k
- Sold
- —
41 trades
0 trades
- Benfer Davidbought
- Menawat Arun Swarupbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STXS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
